Slide 1: Exchange filing cover letter
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com September 21, 2021 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corpor
Slide 2: Investor Presentation Q1 FY22
Investor Presentation Q1 FY22 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Biocon is a global biopharmaceutical company
Biocon is a global biopharmaceutical company that is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. 3
Slide 5: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access to innovation that adds the essential drugs for patients on condition of affordability to As a committed the lowest rung of the accessibility stakeholder of the economic l
Slide 6: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Enzymes Transforming into Building the Base Strategic Global Commercialized Poised for Company a Biopharma Business and Alliance with Mylan Biosimilars for Global Impact Company Experti
Slide 7: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 7,360 Cr 12,000+ Revenue* Total Employees* 1,200+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where our Among Top 10 Global products are Biotech Employers by available Science magazine *Fisca
Slide 8: Battling the pandemic!
Battling the pandemic! Mounting ‘on-site’ infections coupled with lockdown posed significant operational challenges When I came off the ventilator, I was told to be prepared for convalescent plasma therapy. But its need was mitigated by the administration of ALZUMAb-L (Itolizumab), which foiled the
Slide 9: Business Segments
Business Segments 8
Slide 10: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring access Expanding access Partnering to Pushing scientific through quality, throug
Slide 11: Generics: Investing into capacities and capabilities for the future growth
Generics: Investing into capacities and capabilities for the future growth Differentiated API business Growing Formulations Footprint Investments for future growth • 5 state-of-the-art facilities across Bangalore, • Solid oral & parenteral products in both potent & • Expanding our R&D capabilities f
Slide 12: Generics: Q1 FY22
Generics: Q1 FY22 KEY HIGHLIGHTS Q1 FY22 Q1 FY21 COVID-19 led operational and supply chain challenges in API Revenue manufacturing, expected to normalize in the coming quarter ₹486Cr ₹621Cr Gradual ramp-up of Tacrolimus in US while statins’ market share was resilient 22% YoY decrease Entered Labetal
Slide 13: Biosimilars: Developing biologics for global markets at all scale
Biosimilars: Developing biologics for global markets at all scale Product Status Therapeutic Areas Molecule US Dev. Markets: ex-US MoW5 Biosimilars are an attractive opportunity Pegfilgrastim1 EU, CANZ 1 Trastuzumab EU, CANZ Oncology 1 Bevacizumab EU Robust biosimilar portfolio coupled with 1 Pertuz
Slide 14: Biosimilars: Key updates in Q1 FY22
Biosimilars: Key updates in Q1 FY22 KEY HIGHLIGHTS Q1 FY22 Q1 FY21 Strong growth in BFI business with significant contribution Revenue from COVID-19 portfolio, serving 50,000+ patients ₹758Cr ₹692Cr Steady performance of non-COVID products 10% YoY increase Core EBITDA1 Continued improvement in marke
Slide 15: Novel Molecules: Pushing scientific boundaries to deliver impactful innovations
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress • Phase I multiple ascending dose studies in Type 1 DM patients making progress in Insulin Tregopil- a first-in-class oral, prandial Germany. This trial is in partnership with the US-b
Slide 16: Novels: Q1 FY22
Novels: Q1 FY22 KEY HIGHLIGHTS Equillium had Positive End-of-Phase 1 meeting with the US FDA on Itolizumab for acute GvHD* To initiate a Phase 3 pivotal study on Itolizumab in first-line acute GvHD* in Q4 CY 2021 COMP** approved an Orphan Designation for Itolizumab for the treatment of acute and chr
Slide 17: Research Services (Syngene): A global CRO delivering innovative solutions
Research Services (Syngene): A global CRO delivering innovative solutions Offering integrated research, development and manufacturing services for both small and large molecules, antibody-drug conjugates and oligonucleotides backed by best-in-class bioinformatic services Combining world class resear
Slide 18: Research Services: Q1 FY22
Research Services: Q1 FY22 KEY HIGHLIGHTS Q1 FY22 Q1 FY21 Revenue Growth across all divisions – Discovery, Development and Manufacturing services ₹595Cr ₹422Cr 41% YoY increase Significant contribution of Remdesivir in topline growth Profit Before Tax Mangalore API facility successfully completed IS
Slide 19: Financial Highlights
Financial Highlights 18
Slide 20: Annual Financial Highlights
Annual Financial Highlights FY21 FY20 Biosimilars +21% | Research Services Revenue +13% ₹7,360Cr ₹6,462Cr +9% | Generics +6% Core EBITDA1 +15% ₹2,430Cr ₹2,108Cr Forex loss of ₹9Cr in FY21 vs ₹65Cr of Forex gain in FY20 % margin 33% 33% Gross R&D spends at ₹627Cr in FY21 EBITDA +8% ₹1,907Cr ₹1,765Cr
Slide 21: Quarterly Financial Highlights
Quarterly Financial Highlights Q1 FY22 Q1 FY21 Biosimilars +10% | Research Services Revenue +6% ₹1,808Cr ₹1,712Cr +41% | Generics (22)% Core EBITDA* (1)% ₹531Cr ₹532Cr Forex Gain of ₹17Cr in Q1 FY22 vs ₹4Cr of Forex loss in Q1 FY21 % margin 30% 31% Gross R&D spends at ₹136Cr in Q1 FY22 EBITDA +1% ₹4
Slide 22: Thank You
Thank You INVESTOR RELATIONS CONTACT: Chirag Dalal, Biocon Limited Tel : +91 897 197 4732 Email: chirag.dalal@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: Nikunj.mall@biocon.com 21